Medicare's CAR-T Policy Should Encompass Future Uses, Sites of Care – BIO
Product developers worry coverage might not extend beyond current indications and use in hospitals, based on the draft national coverage determination released by the Centers for Medicare and Medicaid Services.
You may also be interested in...
Product developers and researchers applaud the changes, including dropping "coverage with evidence development" approach.
US Centers for Medicare and Medicaid Services administrator Seema Verma discusses solutions for handling the high cost of gene therapy and the Trump administration’s drug pricing agenda in briefing with reporters.
Draft national coverage decision addresses current indications and hospital sites of care. CMS expects to “leverage” existing FDA post-market data collection requirements but seeks additional data on patient-reported outcomes in some cases.